Clinical characteristics of KRAS mutations in NSCLC and their impact on outcomes to first-line chemotherapy

被引：0
|
作者：
Butaney, Mohit
Porter, Jennifer
Lindeman, Neal Ian
Janne, Pasi A.
Rabin, Michael S.
Marcoux, J. Paul
Johnson, Bruce E.
Jackman, David Michael
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7588
引用
收藏
页数：1
相关论文
共 50 条
  • [41] First-line immune-chemotherapy combination for squamous NSCLC is already a reality
    Hendriks, Lizza E. L.
    Menis, Jessica
    Remon, Jordi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (03) : 819 - 823
  • [42] Real World Report of Clinical Outcomes of Bevacizumab in First-Line or Later-Line Treatment for Patients with Advanced NSCLC
    Wang, Y.
    Hao, X.
    Zhu, Y.
    Hu, X.
    Wang, H.
    Liu, Y.
    Mu, Y.
    Li, J.
    Wen, Y.
    Wang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2078 - S2079
  • [43] Bevacizumab plus chemotherapy extends survival of patients with first-line nonsquamous NSCLC
    不详
    ONCOLOGY-NEW YORK, 2005, 19 (04): : 473 - 473
  • [44] Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis
    Petrelli, Fausto
    Ferrara, Roberto
    Signorelli, Diego
    Ghidini, Antonio
    Proto, Claudia
    Roudi, Raheleh
    Sabet, Mehrdad N.
    Facelli, Sara
    Garassino, Marina C.
    Luciani, Andrea
    Roviello, Giandomenico
    IMMUNOTHERAPY, 2021, 13 (07) : 621 - 632
  • [45] Impact of Clinical Response to First-Line Chemotherapy on Gastric Cancer Patients Treated with Second-Line and Third-Line Chemotherapy
    Kodera, Yasuhiro
    Ito, Yuichi
    Ohashi, Norifumi
    Nakayama, Goro
    Koike, Masahiko
    Fujiwara, Michitaka
    Nakao, Akimasa
    HEPATO-GASTROENTEROLOGY, 2011, 58 (107) : 1041 - 1045
  • [46] KRAS codon 12 and 13 mutations in metastatic colorectal cancer: Predictive marker in first-line bevacizumab-based chemotherapy
    Cunha Pereira, T.
    Salgueiro, F.
    Monteiro, A.
    Felix Soares, R.
    Macedo, F.
    Jacinto, P.
    Paulo, J.
    Bonito, N.
    Marques, M.
    Ribeiro, J.
    Sousa, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S163 - S164
  • [47] Clinical characteristics and treatment outcomes for metastatic early-onset small bowel adenocarcinoma treated with first-line chemotherapy.
    Yamaguchi, Shotaro
    Hirano, Hidekazu
    Sano, Momoko
    Hirose, Toshiharu
    Okita, Natsuko Tsuda
    Shoji, Hirokazu
    Takashima, Atsuo
    Kato, Ken
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 796 - 796
  • [48] Clinical outcomes of intensive versus less intensive first-line chemotherapy for metastatic colorectal cancer
    Yamazaki, Kentaro
    Yuki, Satoshi
    Oki, Eiji
    Sano, Fumikazu
    Makishima, Misako
    Aoki, Kenichi
    Hamano, Tetsutaro
    Yamamoto, Kouji
    FUTURE ONCOLOGY, 2023, 19 (39) : 2569 - 2583
  • [49] Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
    Mok, Tony
    Wu, Yi-Long
    Lee, Jin Soo
    Yu, Chong-Jen
    Sriuranpong, Virote
    Sandoval-Tan, Jennifer
    Ladrera, Guia
    Thongprasert, Sumitra
    Srimuninnimit, Vichien
    Liao, Meilin
    Zhu, Yunzhong
    Zhou, Caicun
    Fuerte, Fatima
    Margono, Benjamin
    Wen, Wei
    Tsai, Julie
    Truman, Matt
    Klughammer, Barbara
    Shames, David S.
    Wu, Lin
    CLINICAL CANCER RESEARCH, 2015, 21 (14) : 3196 - 3203
  • [50] Targeting mutated KRAS in the first-line therapy
    Ijichi, Hideaki
    CLINICAL AND TRANSLATIONAL DISCOVERY, 2024, 4 (02):
12345